{"id":732804,"date":"2023-02-21T05:03:09","date_gmt":"2023-02-21T10:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/"},"modified":"2023-02-21T05:03:09","modified_gmt":"2023-02-21T10:03:09","slug":"abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/","title":{"rendered":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PLZEN, Czech Republic, Feb.  21, 2023  (GLOBE NEWSWIRE) &#8212; AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.<\/p>\n<p align=\"justify\">Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target with a particularly challenging Target Product Profile. AbCheck\u2019s high-class drug discovery platform centered on the Company\u2019s unique microfluidics technology, is designed to overcome target-specific challenges and improve success rates for drug discovery campaigns, paving the way towards next generation protein therapeutics.<\/p>\n<p align=\"justify\">\u201cOver the past months, we have continuously evolved our unique suite of advanced technologies with the ability to discover and develop antibodies against a wide range of targets with therapeutically relevant biological functions,\u201d commented Dr. Volker Lang, Managing Director of AbCheck. \u201cOur proprietary microfluidics platform, which enables functional screening for millions of single cells per day, has been specifically designed to deliver antibodies against targets with particularly complex Target Product Profiles. Building on our proven capabilities of delivering highly promising candidates suitable for clinical development, we are very pleased to offer our new partner our full support towards unlocking novel treatment options for severe neurological disorders.\u201d<\/p>\n<p>\n        <strong>About AbCheck<\/strong>\n      <\/p>\n<p align=\"justify\">AbCheck discovers and optimizes human therapeutic antibodies with one of the industry&#8217;s most versatile technology platforms. Tailored to the specific needs of its customers and their desired Target Product Profiles, we design a personalized approach leveraging both cutting edge (e.g., microfluidics, rabbit mass humanization) and classical (e.g., phage\/yeast display libraries) technologies to provide high quality leads. Flexibly adapting to our partners\u2019 needs, we have proven our capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3lVOP1XC0G_2GrQfczEIczuEZGD5-p-bi5cgKt7jt559EDc3sxu3jKthaBXh_ZKZJHW69m4ehFLf7QaRFwFzYGA7d2O6wXSa2fBPBb_vuq3CekY_GjR34Bf504CkwGAq\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.abcheckantibodies.com\/<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>AbCheck s.r.o.<\/strong><br \/>\n        <br \/>Dr. Volker Lang<br \/>Managing Director <br \/>+420 378 051 500<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-8Ql9YokV1ekK2r7xDuz1oL5g51aDiSnoM440egp-WY_Z9elMA-2_E9Phcfk_LIC6JzvzURu4xcvv0THpye5UBWK6b6eTp3SSHGOQriBF7SbxqUJ0-W96a1S95ip_O_H\" rel=\"nofollow noopener\" target=\"_blank\">v.lang@abcheckantibodies.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWM0YWVmZjMtZTYzZC00NTM2LWE1YzAtODgzOTk3NWY1NGZkLTEwMTUzMDc=\/tiny\/Affimed-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm. Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target with a particularly challenging Target Product Profile. AbCheck\u2019s high-class drug discovery platform centered on the Company\u2019s unique microfluidics technology, is designed to overcome target-specific challenges and improve success rates for drug discovery campaigns, paving the way towards next generation protein &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732804","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm. Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target with a particularly challenging Target Product Profile. AbCheck\u2019s high-class drug discovery platform centered on the Company\u2019s unique microfluidics technology, is designed to overcome target-specific challenges and improve success rates for drug discovery campaigns, paving the way towards next generation protein &hellip; Continue reading &quot;AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T10:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target\",\"datePublished\":\"2023-02-21T10:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/\",\"name\":\"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=\",\"datePublished\":\"2023-02-21T10:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/","og_locale":"en_US","og_type":"article","og_title":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target - Market Newsdesk","og_description":"PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm. Under the terms of the agreement, AbCheck will apply its proprietary technology suite comprising a tailored combination of state-of-the-art antibody discovery technologies to delivering antibodies against an undisclosed target with a particularly challenging Target Product Profile. AbCheck\u2019s high-class drug discovery platform centered on the Company\u2019s unique microfluidics technology, is designed to overcome target-specific challenges and improve success rates for drug discovery campaigns, paving the way towards next generation protein &hellip; Continue reading \"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-21T10:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target","datePublished":"2023-02-21T10:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/","name":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=","datePublished":"2023-02-21T10:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MzIzMiM1NDIwNDY2IzIwMDM3MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcheck-announces-collaboration-to-apply-microfluidics-technology-to-the-discovery-of-antibodies-against-challenging-therapeutic-neurology-target\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732804"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732804\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}